Jean-Michel successfully represented four pharmaceutical companies in multiple class actions concerning ranitidine (Zantac) across Canada (Quebec, BC, Ontario and Alberta) seeking billions in damages. With counsel for other defendants, he argued before the BC Supreme Court and successfully defeated certification. Plaintiff in BC ultimately withdrew his appeal (November 2023), while discontinuances were obtained in Ontario (2022) and Alberta (2025).
Your privacy is important to us. By using this site, you agree to data tracking as described in our privacy policy.
The tracking of certain data is required for the operation of the website and therefore cannot be deactivated: choice of language, consent and preference on data tracking, etc.
In return, the tracking of certain data is optional and requires your consent: collect statistics on traffic, analyze visitors’ journeys to improve the functioning of the website, offer personalized offers, etc.